Efficacy of Pleurodesis and EGFR TKI in the Treatment of Lung Cancer-mediated Pleural Effusion with EGFR Mutation

被引：0
|
作者：
Li, Kunlin [1 ]
Zhao, Qian [1 ]
Zhang, Peng [2 ]
机构：
[1] Daping Hosp, Chongqing, Peoples R China
[2] Sichuan Int Studies Univ, Chongqing, Peoples R China
来源：
EUROPEAN RESPIRATORY JOURNAL | 2020年 / 56卷
关键词：
Quality of life; Lung cancer - management; Pleura;
D O I：
10.1183/13993003.congress-2020.1148
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
1148
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer
    Takeda, Masayuki
    Okamoto, Isamu
    Nakagawa, Kazuhiko
    LUNG CANCER, 2015, 88 (01) : 74 - 79
  • [32] At the crossroads: EGFR and PTHrP signaling in cancer-mediated diseases of bone
    Foley, John
    Nickerson, Nicole
    Riese, David J., II
    Hollenhorst, Peter C.
    Lorch, Gwendolen
    Foley, Anne M.
    ODONTOLOGY, 2012, 100 (02) : 109 - 129
  • [33] At the crossroads: EGFR and PTHrP signaling in cancer-mediated diseases of bone
    John Foley
    Nicole Nickerson
    David J. Riese
    Peter C. Hollenhorst
    Gwendolen Lorch
    Anne M. Foley
    Odontology, 2012, 100 : 109 - 129
  • [34] Emerging treatment for advanced lung cancer with EGFR mutation
    Inal, Cengiz
    Yilmaz, Emrullah
    Piperdi, Bilal
    Perez-Soler, Roman
    Cheng, Haiying
    EXPERT OPINION ON EMERGING DRUGS, 2015, 20 (04) : 597 - 612
  • [35] The Correlation between EGFR Mutation Status and DNA Content of Lung Adenocarcinoma Cells in Pleural Effusion
    Du, Yun
    Guo, Xiao
    Wang, Rui
    Ma, Yang
    Zhang, Yan
    Liu, Ying
    Dong, Lvli
    Wu, Juan
    Ji, Xiaokun
    Wang, Heng
    JOURNAL OF CANCER, 2020, 11 (08): : 2265 - 2272
  • [36] Efficacy of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors for Treatment of Malignant Pleural Effusion in EGFR-Mutant Lung Adenocarcinoma Patients
    Lee, K.
    Chung, C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [37] Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation-Positive Non-Small Cell Lung Cancer
    Isomoto, Kohsuke
    Haratani, Koji
    Hayashi, Hidetoshi
    Shimizu, Shigeki
    Tomida, Shuta
    Niwa, Takashi
    Yokoyama, Toshihide
    Fukuda, Yasushi
    Chiba, Yasutaka
    Kato, Ryoji
    Tanizaki, Junko
    Tanaka, Kaoru
    Takeda, Masayuki
    Ogura, Takashi
    Ishida, Tadashi
    Ito, Akihiko
    Nakagawa, Kazuhiko
    CLINICAL CANCER RESEARCH, 2020, 26 (08) : 2037 - 2046
  • [38] EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer
    Nan, Xueli
    Xie, Chao
    Yu, Xueyan
    Liu, Jie
    ONCOTARGET, 2017, 8 (43) : 75712 - 75726
  • [39] Optimisation of EGFR TKI efficiency wild-type EGFR lung cancer
    Raimbourg, Judith
    Cabart, Mathilde
    Joalland, Marie-Pierre
    Decaudin, Didier
    Deplater, Ludmilla
    Lanoe, Didier
    Douillard, Jean-Yves
    Bennouna, Jaafar
    Vallette, Francois
    Lalier, Lisenn
    CANCER RESEARCH, 2015, 75
  • [40] Overcoming EGFR-TKI resistance in EGFR-mutated lung cancer
    Gardizi, M.
    Scheffler, M.
    Bos, M.
    Geist, T.
    Heukamp, L.
    Nogova, L.
    Toepelt, K.
    Fernandez-Cuesta, L.
    Culmann, H.
    Kaminsky, B.
    Panse, J.
    Becker, C.
    Mattonet, C.
    Serke, M.
    Schmitz, S.
    Schnell, R.
    Galetke, W.
    Hekmat, K.
    Buettner, R.
    Wolf, J.
    ONKOLOGIE, 2013, 36 : 30 - 30
12345